EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Human FGF1ΔHBS Gene Therapy as Treatment for Metabolic Dysfunction-Associated Steatohepatitis in ApoE-KO Mice

Yingjian Li, Xiaodan Hui, Chunjie Gu, Qian Lin iD, Ahmed Abdelbaset-Ismail, Zixuan Xu, Suchen Yadav iD, Hongbiao Huang, Jason Xu, Sara E Watson, Kupper A Wintergerst iD, Lu Cai iD und 2 weitere

Cells · 2026

DOI: 10.3390/cells15050387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Yingjian Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Fatty Liver, Fibroblast Growth Factor 1, Apolipoproteins E. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH Common Fund, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) is rising worldwide. hFGF1ΔHBS, a variant of human fibroblast growth factor 1 with three substitutions in its heparin-binding sites, was previously shown by our group to ameliorate fatty liver. However, hFGF1ΔHBS also significantly modulates systemic metabolism, making it unclear whether its hepatic benefits arise from direct liver-specific actions. Additionally, its poor pharmacokinetic profile underscores the need for alternative delivery strategies. Here, we employed adeno-associated virus serotype 8 under the thyroxine-binding globulin promoter (AAV8-TBG) to achieve sustained, hepatocyte-specific expression of hFGF1ΔHBS. In high-fat-, high-cholesterol-diet-fed apolipoprotein E knockout mice, liver-directed hFGF1ΔHBS expression markedly reduced hepatic steatosis, inflammation, and fibrosis, independent of changes in body weight, blood glucose, insulin sensitivity, body composition, or circulating triglyceride and cholesterol levels. Mechanistically, hFGF1ΔHBS gene transfer normalized fatty acid synthesis and suppressed fatty acid uptake by downregulation of stearoyl-CoA desaturase-1 and cluster of differentiation 36. Importantly, these therapeutic effects were achieved without inducing hepatic hyperproliferation, as evidenced by unchanged expression of proliferating cell nuclear antigen and antigen Kiel 67. Collectively, our findings demonstrate that hFGF1ΔHBS exerts direct hepatoprotective effects and that AAV8-TBG-mediated liver-directed hFGF1ΔHBS delivery represents a safe and effective strategy for treating MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyFatty LiverFibroblast Growth Factor 1Apolipoproteins EAnimalsHumansMiceDependovirusMice, Knockout, ApoEMaleLiverGene Therapy AgentsMice, Inbred C57BL

Stichwörter der Autor:innen

AAV8 gene therapyMASHhFGF1ΔHBSsystemic metabolism

Substanzen

Fibroblast Growth Factor 1Apolipoproteins E

Autor:innen und Institutionen

  • Pediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
  • Touchstone Diabetes Center, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
  • Wendy Novak Diabetes Institute, Norton Children's Hospital, Louisville, KY 40202, USA.
  • Norton Children's Endocrinology, Department of Pediatrics, University of Louisville, Norton Children's Hospital, Louisville, KY 40202, USA.
  • The Center for Integrative Environmental Health Sciences, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
  • Department of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.

ORCID-Profile: Qian Lin, Suchen Yadav, Kupper A Wintergerst, Lu Cai

Förderung

  • NHLBI NIH HHS
  • NIH Common Fund
  • National Institutes of Health
  • Kentucky Pediatric Cancer Research Trust Fund
  • Jewish Heritage Fund for Excellence Research Enhancement Grant Program at the University of Louisville School of Medicine

Zitieren

APA

Li, Y., Hui, X., Gu, C., Lin, Q., Abdelbaset-Ismail, A., Xu, Z., Yadav, S., Huang, H., Xu, J., Watson, S. E., Wintergerst, K. A., Cai, L., Deng, Z., & Tan, Y. (2026). Human FGF1ΔHBS Gene Therapy as Treatment for Metabolic Dysfunction-Associated Steatohepatitis in ApoE-KO Mice. Cells. https://doi.org/10.3390/cells15050387

Vancouver

Li Y, Hui X, Gu C, Lin Q, Abdelbaset-Ismail A, Xu Z, et al. Human FGF1ΔHBS Gene Therapy as Treatment for Metabolic Dysfunction-Associated Steatohepatitis in ApoE-KO Mice. Cells. 2026. doi:10.3390/cells15050387

BibTeX
@article{Li2026,
  author = {Li, Yingjian and Hui, Xiaodan and Gu, Chunjie and Lin, Qian and Abdelbaset-Ismail, Ahmed and Xu, Zixuan and Yadav, Suchen and Huang, Hongbiao and Xu, Jason and Watson, Sara E and Wintergerst, Kupper A and Cai, Lu and Deng, Zhongbin and Tan, Yi},
  title = {Human FGF1ΔHBS Gene Therapy as Treatment for Metabolic Dysfunction-Associated Steatohepatitis in ApoE-KO Mice},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15050387}
}
Kostenlos starten →